PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis.

Robert SeifertKatharina KesselKatrin SchlackManuel WeberKen HerrmannMaximilian SpankeWolfgang P FendlerBoris HadaschikJens KleesiekMichael SchäfersMatthias WeckesserMartin BoegemannKambiz Rahbar

Published in: European journal of nuclear medicine and molecular imaging (2020)

PSMA-TV was a statistically significant negative prognosticator of overall survival in patients receiving Lu-PSMA therapy. PSMA-TLQ was an independent and superior prognosticator of overall survival compared with PSMA-TV.

Keyphrases

pet ct
pet imaging
prostate cancer
positron emission tomography
bone marrow